Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Liminal Biosciences Inc market cap is $19.82M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Liminal Biosciences Inc 52 week high is $8.50 as of November 15, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Liminal Biosciences Inc 52 week low is $3.10 as of November 15, 2026.
Liminal Biosciences Inc stock price today is $8.48.
Liminal Biosciences Inc stock price yesterday was $8.48.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Liminal Biosciences Inc's P/E ratio is 27.62.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Liminal Biosciences Inc P/B ratio is 1.702.
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company's operations. Liminal Biosciences Inc's EBITDA is -0.25.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Liminal Biosciences Inc 50-day moving average is $8.42.
